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ABSTRACT 
Oral therapy of NSAIDs for treatment of rheumatoid arthritis causes gastric irritation and ulceration. In the present study transdermal patch of 
ketoprofen was developed using hydroxyl propyl methyl cellulose E5 and Eudragit S100. Patches were prepared by solvent evaporation method. 
Optimization was carried out by 32 factorial design with polymer concentration (HPMC E5) and plasticizer concentration (propylene glycol) as 
independent variables. Patches were evaluated for folding endurance, surface pH, drug content, percent moisture content, water uptake and 
swelling studies. Ex vivo permeation studies of optimized patch was performed using Franz diffusion cell while bioadhesion force and tensile 
strength were measured by using texture analyzer. Hydrophilic nature, swelling ability and wettability of polymer and plasticizer were 
responsible for increase in flux and bioadhesion with increase in their concentrations in the factorial batches. Swelling index of all formulations 
was in the range of 17.3 ±1.2 to 65.29 ±4.78 up to 3h. Flux obtained from all batches was in the range of 3.37±0.23 to 5.43±0.13µg/h/cm2. Anti-
inflammatory studies using carrageenan-induced rat paw edema showed greater paw swelling reduction in case of ketoprofen patch. Cumulative 
percent drug permeation of optimized patch through nylon 66, Wistar rat skin and cadaver skin was found to be 92.3% >86.28 %>63.42% in 8h, 
while flux order was 6.073> 5.442 > 2.219 µg/h/cm2 respectively. The study concludes that transdermal patch of ketoprofen will be more 
efficacious with absence of gastric irritation observed in oral formulations. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic, progressive 
inflammatory disease of the joints characterized by synovial 
proliferation and inflammatory and immunological 
processes. These mechanisms lead to irreversible 
degradative and erosive changes in the articular cartilage 
and juxta articular bone. RA affects multiple joints, most 
commonly small joints of the hands, feet and cervical spine, 
but larger joints like the shoulder and knee can also be 
involved1,2. 
Non-Steroidal Anti-Inflammatory Drug (NSAID) and steroids 
are used to reduce inflammation thereby decreasing pain 
and improving function. Disease-Modifying Antirheumatic 
Drugs (DMARDs) are required to inhibit the underlying 
immune process and prevent long-term damage1,3. NSAIDS 
lead to gastrointestinal side effects such as dyspepsia to 
gastric bleeding4. The acidic character of NSAIDS may lead to 
local irritation, and lesions on the gastrointestinal mucosa 
are known as NSAIDS gastropathy5. 
Ketoprofen (KTF) is a propionic acid derivative which causes 
inhibition of Cyclooxygenase-2 (COX-2), an enzyme involved 
in prostaglandin synthesis via the arachidonic acid pathway. 
This results in decreased levels of prostaglandin that 
mediate pain, fever and inflammation. KTF is a non-specific 
cyclooxygenase inhibitor and inhibition of COX-1 is 
responsible for its side effects, such as GI upset and 
ulceration6. Currently available marketed dosage form of 
KTF are enteric coated and extended release tablets, topical 
gel, liquid spray, suppositories, extended release capsules 
and formulation based on transfer some technology for 
direct application on the skin has been developed7. 
Transdermal therapeutic systems are defined as, discrete 
dosage forms which, applied to the intact skin, deliver the 
drugs at a controlled rate to the systemic circulation via skin 
and this delivery system offers an advantageous alternative 
to conventional delivery system such as injections or oral 
delivery8,9. Transdermal drug delivery system (TDDS) offers 
many advantages such as reduced side effects, less frequent 
administration to produce the desired constant plasma 
concentration associated with improved patient compliance, 
Rao et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(2):197-205 
ISSN: 2250-1177                                                                                  [198]                                                                                 CODEN (USA): JDDTAO 
elimination of the first‐pass effect and sustained drug 
delivery. NSAID are mostly used for the preparation of 
transdermal patches for treatment of pain or arthritis10. 
The objective of the present study was to design suitable 
transdermal matrix patch of (KTF) for the treatment of 
rheumatoid arthritis. The transdermal drug delivery system 
was optimized using 32 factorial designs. The patches were 
characterized for physicochemical parameters and also 
evaluated for swelling studies, ex-vivo effects of optimized 
batch on cadaver skin and rat skin and pharmacodynamics 
studies. 
MATERIALS AND METHODS 
Ketoprofen was obtained from BEC Chemicals Pvt. Ltd. Roha-
Raighad, Mumbai, India. Hydroxy Propyl Methyl Cellulose E5, 
Eudragit S100 was procured from Evonik industries, 
Mumbai. Tween 80, Propylene Glycol, Glycerin, Ethyl 
Cellulose, Dibutyl phthalate was procured from Research Lab 
Fine Chem. Industries, Mumbai. All raw materials and 
chemical reagents used were of analytical grade and 
procured locally. 
Pre-optimization study 
During pre-optimization studies, polymers like Hydroxy 
Propyl Methyl Cellulose E5 (HPMC), Eudragit S100 (EGT), 
Xanthan gum, Sodium alginate, Polyvinyl pyrrolidone (PVP), 
Hydroxyl Ethyl Cellulose (HEC), Methyl Cellulose, plasticizers 
like Polyethylene Glycol 400 (PEG),  Propylene glycol(PG),  
Dibutyl phthalate (DBT) and permeation enhancers like 
tween 80, oleic acid, Dimethyl sulfoxide (DMSO) were used 
for formulating transdermal matrix patches. Patches were 
prepared using each of these polymers in different ratios like 
1:1, 1:2, 3:1:2, 2:2:1, 2:1 by solvent casting method.  
Development of transdermal patch by solvent 
evaporation technique 
The transdermal patches were prepared by solvent 
evaporation technique11. Polymeric solutions were prepared 
using polymers, HPMC E5 and EGT S100 in different ratios of 
3:1, 4:1, 5:1 in mixture of chloroform: methanol (1:1 v/v). 
KTF was then added to this solution by calculating area of 
the petri dish so that final patch of 1cm would contain 50 mg 
of drug. Plasticizer (PG) and penetration enhancer (Tween 
80) were added separately to the polymeric solution and 
poured in petri dish which was previously lubricated with 
glycerin and allowed to air dry overnight.  
Preparation of backing membrane  
Backing membrane solution containing 500mg of ethyl 
cellulose and 2% w/v DBT in 10ml acetone was poured into 
the glass petri dish and air dried for 1h12.Patch with backing 
membrane was prepared by pouring backing membrane 
solution on preformed patch. Circular patches (diameter- 
9.2cm) were removed from petridish and placed in 
desiccators. 
Drug polymer compatibility studies 
Compatibility of drug and polymers like HPMCE5, EGT S100 
was analyzed by FT-IR (Shimadzu- FTIR- 460 plus) for 
determination of drug polymers interactions. Drug was 
mixed with polymer in 1:1 ratio and samples were stored for 
30 days at 40 ± 2ºC/ 75 ± 5% RH. FT-IR spectra of these 
samples were then obtained after 30 days. 
Experimental design  
Optimization of transdermal patches was performed using a 
randomized 32 full factorial design.  This design was carried 
out with Design Expert 9 software (State- Ease Inc, 
Minneapolis, USA) to study effect of two factors on response 
variables like flux, tensile strength and bioadhesion force. 
The two factors were ratio of polymers (HPMC: EGT S100) 
and concentration of plasticizer (PG) and three levels coded 
as -1, 0 and +1 respectively. The selected factor levels and 
composition of 32 factorial designs are given in Table 1. 
 
Table 1: Composition for Trial Runs with Factor Level of 32 Factorial Design 
Formulation 
code 
Drug (KTF) 
(mg) 
HPMC E5:EGT 
S 100 
HPMC E5 
(g) 
EGT S100 
(g) 
Tween 80 
(g) 
PG 
(g) 
Methanol :chloroform  
1:1 (ml) 
F1 50 3:1 (-1) 0.6 0.2 0.2 0.3(-1) 20 
F2 50 3:1 (-1) 0.6 0.2 0.2 0.4(0) 20 
F3 50 3:1 (-1) 0.6 0.2 0.2 0.5(1) 20 
F4 50 4:1 (0) 0.8 0.2 0.2 0.3(-1) 20 
F5 50 4:1 (0) 0.8 0.2 0.2 0.4(0) 20 
F6 50 4:1 (0) 0.8 0.2 0.2 0.5(1) 20 
F7 50 5:1 (1) 1 0.2 0.2 0.3(-1) 20 
F8 50 5:1 (1) 1 0.2 0.2 0.4(0) 20 
F9 50 5:1 (1) 1 0.2 0.2 0.5(1) 20 
Factor level shown in bracket (-1) low, (0) medium (1) high while EGT–Eudragit and PG-Propylene glycol. 
 
Physicochemical evaluation of Transdermal Patches 
Thickness, flatness and weight variation 
The thicknesses of the formulated patches were measured at 
four different points using a thickness dial gauge (Mitutoyo, 
Japan) and average thickness was calculated13. To study 
flatness, 3 longitudinal strips were cut out from each patch. 
The length of each strip was measured and the variation in 
length because of non-uniformity in flatness was measured 
by determining percent constriction, with 0% constriction 
equivalent to 100% flatness14. Constriction (%) = (L1-L2) / 
L2 X 100 Where, L1 initial length of each strip, L2 final 
length. Such determination was performed for each 
formulation and mean value was calculated15. 
Surface pH 
The surface pH of the patches was determined by placing the 
probe of the pH meter in close contact with the wetted 
surface of the patch. The pH of three randomly selected films 
was measured using a pH meter (Deluxe pH meter 101, 
India)16. 
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Folding endurance 
The films were repeatedly folded in the same place 300 
times or until they broke, which ever was less, to determine 
their folding endurance17. 
Drug content 
The drug content was determined using a UV-visible 
spectrophotometer (Lab India Analytical UV 3000, India). 
Patches of 1cm2 were cut and placed in test tubes containing 
10ml methanol for 24h to extract the drug. This solution was 
filtered and further diluted with methanol and analyzed by 
UV-visible spectrophotometry at a wavelength of 254nm. 
Drug content was calculated using equation obtained from 
the standard calibration curve of KTF18. 
Determination of percent moisture content and 
moisture uptake 
The films were weighed individually and kept in a 
desiccators containing activated silica at room   temperature 
for 24h19. Individual films were weighed repeatedly until 
they show constant weight. Percentage moisture content was 
calculated by using the following formula: 
Percent Moisture Content=  
Initial weight – final weight / final weight×100 
The films were also subjected to moisture uptake studies by 
exposing the patches to 84% RH and ambient temperature in 
a desiccators containing saturated solution of potassium 
chloride until a constant weight was achieved20. Then the 
films were weighed and percentage moisture uptake was 
calculated by using the following formula: 
Percentage moisture uptake =  
[Final wt−Initial wt. /Initial wt.]×100 
Swelling studies 
Patches of 1cm2 were weighed separately (initial weight= 
W1) and placed in petri plates containing 6ml distilled water. 
The swollen films were weighed individually at regular time 
intervals up to3h (Final weight = W2).  Swelling index of 
each system was calculated using the following formula21: 
Swelling index= (W2- W1) /W1× 100 
Ex vivo permeation studies 
The permeation of KTF from all transdermal patches were 
studied using excised rat skin. Male Wistar rats were 
sacrificed by cervical dislocation with prior permission from 
the Institutional Animal Ethics Committee (Protocol 
approval No. CPCSEA/IAEC/PT-03/01-2K 16). Skin was 
shaved and the subcutaneous fat and connective tissue was 
removed and the excised skin was washed with phosphate 
buffer pH 6.8 and skin was stored in the freezer at -20oC. 
Saline phosphate buffer pH 7.4 (7ml) was filled in the 
receiver compartment of the Franz diffusion cell. Excised rat 
skin was positioned between the donor and receiver 
compartment and the transdermal patch of area 3.14cm2 
was placed onto the skin. The buffer was continuously 
stirred with a magnetic bead and the entire assembly was 
maintained at 32 ± 0.5oC. Samples were withdrawn at 1h 
time intervals up to 8h and analyzed by UV-visible 
spectrophotometry at 258nm to determine the amount of 
drug permeated. The flux (J) was calculated from the graph 
slope of percent permeation Vs time in h22, 23. 
Tensile strength 
Tensile strength of the patches was determined using a 
texture analyzer (CT-3/10,000, Brookfield, USA) equipped 
with a 10kg load cell. Patches of 2cm2 area were randomly 
selected and fixed between the two clamps of probe and for a 
hold time of 60s. The film was pulled apart at a speed of 
2.0mm/s by the upper clamp24. The peak load corresponding 
to the time the film broke was recorded. The tensile strength 
was calculated using formula: 
Tensile Strength (M Pa) =  
Peak load at break (kg) / Initial cross-sectional area (mm2)×9.80665 
Bioadhesion studies 
The bioadhesion force was measured using Texture Analyzer 
(CEB Texture Analyzer, Make-Brookfield Engineering Labs, 
Inc., Model Texture Pro CT V1.4 Build 17) equipped with a 
100g load cell. The measurement of bioadhesive force was 
done on excised rat skin as the model membrane. The rat 
skin was tied to the probe and the patch was placed between 
two circular discs which were at lower Perspex support and 
was wetted with 10 µl of distilled water. The probe and 
circular cavity were aligned to ensure that film comes into 
direct contact with exposed surface of rat skin membrane. 
The probe with the skin was lowered at a speed of 1.0mm/s 
and skin was kept in contact with the patch for 20s with 80g 
load. Data collection and calculations were performed using 
Texture- Pro CT V1.3 Build 14 software25. 
Ex vivo permeation studies on cadaver skin 
Human cadaver skin was obtained from Sassoon Hospital 
after taking prior permission of Head of Forensic Medicine 
and Toxicology Department. All subcutaneous fat from 
freshly excised human cadaver epidermis (from the thigh 
region of a male cadaver of age 41 years within 24–48h post-
mortem) was removed with the scalpel. The sample was cut 
to appropriate size and kept in saline phosphate buffer pH 
7.4 solutions overnight at room temperature and then 
washed several times with phosphate buffer pH 7.4 before 
use26. The ex-vivo permeation of the optimized patch was 
studied for duration of 8h using Franz diffusion cell by 
previously reported procedure27. 
Skin irritation studies 
The irritancy of the selected films was evaluated by Draize 
method on Wistar rats (200-210gm). The rats were 
anesthetized with ether and dorsal side of the rats was 
shaved 24h before the beginning of the experiment. The 
animals were divided into 3 groups each consisting of 6 rats. 
Group A served as control; Group B as standard and received 
0.5ml of a 0.8% v/v aqueous formalin solution as a standard 
irritant. Group C was the test group which received 
medicated films for 3 days (new patch was applied daily). 
The application sites were examined for edema and 
erythema after 24h and 72h and then graded from 0-4 
according to a visual scoring scale by the same investigator; 
the final score represented the average of the 24 and 72h 
readings. The primary irritancy index (PII) was determined 
for each preparation by adding the edema and erythema 
scores, the formulations was accordingly classified as non-
irritant if PII<2, irritant if (PII=2-5) and highly irritant if 
PII=5-818. 
Pharmacodynamic test (Carrageenan induced edema 
model) 
Carrageenan induced rat hindpaw edema method was used 
to evaluate the anti-inflammatory activity of the formulation. 
Wistar rats weighing approximately 150-200g were divided 
into 3 groups each consisting of 6 animals. In each group the 
left hind paw of each rat was marked, just beyond tibiotarsal 
junction, so that every time the paw is dipped up to the fixed 
mark to ensure constant paw volume. Group A served as 
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control group while group B was the standard group which 
was given KTF suspension orally (15mg/kg; 4mg/ml KTF 
suspension). The transdermal patch was applied to Group C 
after removing the hair from the dorsal side of rats. The paw 
volume was measured with a plethysmometer prior to the 
injection. Acute inflammation was produced by injecting 0.1 
ml of 1% w/v carrageenan solution in the sub plantar region 
of the left hind paw. The paw volume was determined after 
0, 1, 2, 4, and 6h.The percentage paw swelling was calculated 
by the following formula28. 
% paw swelling= (B -A)×100/A 
Where,  
A is the paw volume before induction of edema and 
B is the paw volume measured hourly after induction of 
edema. 
Stability studies  
The stability studies were conducted as per ICH guidelines to 
investigate the influence of temperature and relative 
humidity on the drug content in different formulations. The 
optimized transdermal formulations were stuck on an 
adhesive backing membrane, covered with a release liner 
and stored in an aluminum foil. They were subjected to 
stability studies for 3 months using storage conditions 40 ± 
2˚C/ 75 ± 5 % RH as per ICH guidelines29. Samples were 
taken after third month and evaluated for percent drug 
content, thickness, percent flatness and folding endurance.  
RESULT AND DISCUSSION  
Pre optimization results  
The polymer combination of Xanthan gum: HPMC E5: MC 
produced sticky and opaque films. Some of the polymers like 
combination of PVP, sodium alginate and methyl cellulose 
formed brittle and inferior quality film. HPMC E5 and PVP in 
a ratio of 1:1 with PG as plasticizer and oleic acid as 
permeation enhancer had very good film properties. Xanthan 
gums in combination with other polymers produce sticky 
films.  The polymers which produced transparent and 
flexible films with smooth appearance were found to be 
HPMC E5 and EGT S100 in a ratio of 2:1 with propylene 
glycol as plasticizer, tween 80 as permeation enhancer using 
methanol and chloroform (1:1 v/v) as solvent system. The 
film so produced was evaluated for pH, folding endurance, 
thickness, percent weight variation and percent drug 
content. Thickness, percent weight variation and drug 
content was found to be 0.27±0.006, 0.25±0.1 and 
99.49±0.098 respectively. The pH and folding endurance 
were found to be 6.4±0.04 and 398±0.083 respectively. 
Drug polymer compatibility studies 
FTIR analysis of  HPMC E5 and EGT S100 film formulations 
containing KTF did not reveal any additional peak for the 
drug are shown in Figure 1 which pointed to lack of 
interaction between drug and polymers used in the films. 
FTIR spectra showed compatibility of KTF with HPMC E5,  
EGT S100, and the functional group signals observed were -
OH stretch (Carboxylic acid), C=C (Aromatic) stretch, C-O 
(Phenolic) stretch, C=O (Ketone) stretch, O-H (Carboxylic 
acid) Bending, C-H (Aromatic) in plane Bending,  C=O 
stretching and bending at wave number range 2977.55, 
1597.73-1443.46, 1284.36-1319.07, 1698.98, 1419.35, 
1078.01-1133.94, 1133.94-1284.36 cm-1respectively. 
 
Figure 1: FTIR Spectra of KTF (A), KTF + HPMC E5 (B) and 
KTF + EGT S 100 (C) and KTF+HPMC E5+EGT S100 (D) 
Optimization 
A 32 factorial design was employed to investigate the effect of 
independent variables on flux, tensile strength, and 
bioadhesion force. This design was carried out with Design 
Expert 9 software (State- Ease Inc, Minneapolis, USA) to 
study effect of polymer combination of HPMC E5: EGT S 100 
and plasticizer as PG. The two factors HPMC E5: EGT S100 
ratio and PG were used at three levels -1, 0 and +1 for 
optimization is shown in Table 1. 
Ex vivo permeation studies 
Ex vivo permeation studies of KTF film formulation through 
rat skin showed slow and sustained permeation of the drug 
up to 8h are shown in Figure 2. The rank order of drug 
permeation from films was found to be F9>F8>F7 
>F6>F5>F4>F3>F2>F1. The patch (F9) containing higher 
polymer concentration of HPMC E5 and plasticizer 
concentration (2.5% w/v) showed maximum flux (5.43±0.13 
µg/h/cm2).  It has been widely reported that addition of 
hydrophilic component to an insoluble film former leads to 
enhanced release rate constant30. Permeation study revealed 
that drug release increases as plasticizer and bioadhesive 
polymer concentration increases. F9 patch maximum release 
of 86.28 % in 8h among other patches.  
  
 
Figure 2: Permeation profiles of KTF from all the nine 
formulations. 
F1    F2      F3      F4    F5                 
F6    F7     F8    F9  
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Flux is rate of mass transfer across a unit surface area of a 
barrier and it gives idea related to permeability31. The 3D 
graph showed (Figure 3) that the flux across the membrane 
increased with increase in polymer and plasticizer 
concentration. This could be due to the extensive swelling of 
the hydrophilic polymer and plasticizer32. PG was used as 
plasticizer which has additional property of penetration 
enhancer33, 34 and tween 80 (1%w/v) that may result in 
enhancement of permeation and flux. Penetration 
enhancement effect of tween 80 is due to interaction with 
intracellular protein to enhance penetration through the 
corneocytes, and disruption of the highly ordered structure 
of stratum corneum lipid with an increase in intercellular 
diffusivity35. PG can absorb moisture into the film because of 
its humectants ability, thus contributing to higher flux, 
though it has been used as a plasticizer in the patches36. 
ANOVA analysis of the coefficients of the polynomial 
equations (eq.1) and the F-value of 32.71 implied that the 
quadratic model is significant.  
Flux = 4.02+0.85 A + 0.26 B+0.10AB + 0.20 A2 +0.085 B2 .....(1) 
Where, 
A- Polymeric concentration (HPMC E5: EGT S100), 
B- plasticizer concentration (PG) 
Equation (1) showed that high levels of factor A gave high 
value of flux as evident by the higher coefficient. These 
results confirm the interpretation of response surface 
graphs.
 
 
Figure 3: 3D response surface plot showing the influence of HPMC E5: EGT S100 and PG concentration on the flux, 
Tensile strength and bioadhesion force. 
 
Tensile strength 
The data for all formulations for tensile strength (Table 2) 
indicated that films have sufficient tensile strength. It is 
evident from the contour and response surface plots (Figure 
3) that the tensile strength increases as the concentration of 
plasticizer increases. Polymer concentration also has an 
effect on tensile strength which can be attributed to the 
excellent film forming properties of SHPMC E5 and EGT 
S10037.  
The same is evident in the 3D response surface plots (Figure 
3). Plasticizers cause a reduction in polymer-polymer chain 
secondary bonding and form secondary bonds with the 
polymer chains instead. The reasons for the use of 
plasticizers in transdermal drug delivery systems are the 
improvement of film forming properties and the appearance 
of the film38,39. Propylene glycol may be forming hydrogen 
bonds with HPMC E5 resulting in greater flexibility of films 
at higher plasticizer concentration. When both factors are 
increased simultaneously a prominent rise in the tensile 
strength was observed. Also it is very noticeable that high 
polymer concentration and low plasticizer concentration did 
not result in significant increase in the tensile strength. 
Reason behind increase in tensile strength after increase 
polymer and plasticizer could be cross linking structures of 
polymer (HPMC E5) that improves its elongation ability and 
reduction of fragility of polymer by plasticizer40. 
The coefficients of the polynomial equations (eq.2) and the 
model F-value of 27.73 supported the above findings. 
Tensile Strength = 6.00 + 2.39A+2.68B + 1.57AB-0.89A2 -0.32B2……(2) 
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Table 2:  Responses of Factorial Design Formulations 
Formulation code 
Flux (µg/h/cm2) 
± SD 
 
Tensile strength (MPa X 
10-3)± SD 
Bioadhesion force 
(N X 10-2) ± SD 
F1 3.37±0.23 1.70 ±0.42 1.17 ±0.23 
F2 3.41±0.12 2.40 ±0.78 1.47 ±1.86 
F3 3.52±0.02 3.43 ±1.78 1.86 ±0.07 
F4 3.69±0.19 2.14 ±0.83 3.04 ±0.42 
F5 3.98±0.42 6.73 ±1.35 4.31±1.12 
F6 4.55±0.34 8.49 ±0.12 5.003±0.39 
F7 4.87±0.49 3.38 ±0.75 5.073 ±0.16 
F8 5.07±0.04 7.10 ±1.09 5.39 ±1.55 
F9 5.43±0.13 11.4 ±1.87 5.68 ±1.74 
Values are expressed as mean of triplicate reading ± standard deviation 
 
Bioadhesion Force 
Bioadhesion of the patches may be attributed to the wetting 
and swelling of HPMC E5 and penetration of the polymer 
chains into the cracks or crevices of the skin41. This can be 
correlated with the swelling index of the patches which is 
discussed in further section. Formulation F9 having a high 
swelling index value of 65.29 ± 4.78 % showed good 
bioadhesion properties. The contour and 3D response 
surface plots (Figure 3) show that the bioadhesion force was 
found to increase with increase in the concentration of 
HPMC E5. Similarly increase in plasticizer (PG) 
concentration also enhanced adhesion due to softening effect 
exerted by the plasticizer42. 
The final (eq.3) of Bioadhesion force in terms of coded 
factors is as follows: 
Bioadhesion Force= 4.17 + 1.94 A + 0.54B - 0.021 AB -0.68A2 - 0.086B2 
…….(3) 
The Model F-value of 24.55 implied that the quadratic model 
is significant.  
Validation of optimum design 
To obtain an optimum formula and justify the validity of the 
optimization, the desirability approach was used. Design 
expert software generated four optimum batches (O1 to O4) 
based on the input selection criteria which was flux in the 
range of 5 to 6µg/h/cm2, tensile strength 10 X 10-3MPa and 
12 X 10-3 MPa and bioadhesion force in the range of 5 X 10-2 
to 6 X 10-2 N (Table 3). All optimum batches were found to 
have desirability of approximately 1. Comparison of 
predicted and observed values and residual error for batch 
O1 were found to be in good agreement for all the three 
responses. Also, desirability about 0.991 and low magnitude 
of residual error designates a high prognostic ability of 
response surface methodology. Hence the optimum 
formulation O1 was selected for the further 
pharmacodynamic studies. 
  
Table 3: Comparison of Observed and Predicted Responses for Validation Batches 
Batch 
code 
Polymer 
(g) 
Plasticizer 
(g) 
Tensile Strength 
(MPa X 10-3) 
Flux 
(μg/h/cm2) 
Bioadhesion Force 
(N X 10-2) 
Desirability 
   P* O* P* O* P* O*  
O1 1.200 0.495 11.26 11.24 5.48 5.44 5.857 5.961 0.992 
O2 1.200 0.492 11.15 11.16 5.47 5.45 5.846 5.765 0.987 
O3 1.200 0.474 10.486 10.47 5.38 5.27 5.77 5.531 0.949 
O4 1.179 0.500 11.204 11.21 5.37 5.37 5.80 5.845 0.980 
P*- predicted value, O*- observed value 
 
Evaluation of factorial transdermal patches 
Thickness, flatness, weight variation and drug content 
The nine transdermal patches, prepared as per 32 factorial 
designs, were subjected to preliminary evaluation. All the 
patches were found to be very transparent, flexible and 
uniform in appearance. The thickness of the patches was 
found to be in the range of 0.173±0.015 to 0.27±0.012mm 
thickness confirmed that the patches prepared were uniform 
in thickness,  while  the  percent weight variation of patch 
ranged between 0.0927±0.0351 to 0.1209±0.0027g.The 
percent flatness study showed that all the formulations (F1 
to F9) had the same strip length before and after their cuts, 
with percent flatness range between 98.39±0.1 to 
99.83±0.9%. All patches had a smooth, flat surface with no 
constriction43,44. The drug content was found to be in range 
of 97.45±0.19 to 99.87±0.47 indicated that the drug was 
uniformly dispersed in the polymeric matrix patch. 
Surface pH 
The surface pH value of all patches (6.3 to 6.5) was close to 
human skin pH (6.4) which means that there will be no skin 
irritation and therefore the patches will have good  patient 
compliance as the patch was intended for once-a-day 
application. A very high and low pH value can be harmful to 
the skin45. 
Folding endurance 
The folding endurance of all patches were above 300 thus 
considered satisfactory to reveal good patch properties46,47 
and F1 to F3 batches displayed lower folding endurance 
171±0.89 to 252±0.42 hence, all patches indicated that the 
patches would retain their integrity and not break or crack 
during general skin folding due to bodily movements46. 
Higher folding endurance supports the results of tensile 
strength48. 
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Percent moisture content and moisture uptake 
The moisture content in the patches ranged from (2.7% to 
6.8% w/w). The moisture uptake in the formulations ranged 
from (1.34% to 3.75% w/w) in a span of 24 h. The moisture 
absorption and moisture content was found to increase with 
increasing concentration of hydrophilic polymers (HPMC 
E5)37 as well as hydrophilic plasticizer (PG). Small moisture 
content in the formulations is desirable as it helps the films 
to remain stable and avoids formation of a completely dried 
and brittle film11. 
Swelling index 
Swelling behavior of films as a function of time is illustrated 
in Figure 4. Formulation F9 having highest concentrations of 
HPMC E5 polymers was found to have the highest swelling 
index of 65.29±4.78 as HPMC E5 as hydrophilic polymer has 
high capacity of water uptake49,50. The polymer will then 
undergo simultaneous swelling, dissolution and diffuse into 
the bulk medium resulting in erosion of the polymer51. 
However, an excessive water uptake causes a leakage in 
cohesiveness of dosage forms transforming the formulation 
into over-hydrated slippery mucilage.  This will result in a 
drop in adhesive strength due to disentanglement at the 
polymer tissue interface21. The rate and the extent of patch 
hydration and swelling also affects the patch adhesion and 
consequently the drug release from the patch52. In our study 
the patches were found to retain their integrity as only a 
nominal amount of water was taken up in a span of 3h. 
 
 
Figure 4: Swelling study of KTF transdermal Patch. 
1 h [ ] 2 h [ ] 3h [ ] 
 
Ex vivo skin permeation in cadaver skin 
Permeation study of optimized batch (O1) through human 
cadaver skin was carried out using Franz diffusion cell. 
Permeation profile of optimized (O1) patch was slower and 
sustained release up to the 8h was obtained. The cumulative 
percent drug permeated at 8h was found to be 63.42 % 
(Figure 5) and flux was computed as 2.219 ±0.68µg/h/cm2. 
 
Figure 5: Permeation profiles of optimized batch 
through different membranes. 
( ) cadaver skin, ( )Wistar rat skin,   
(  ) nylon membrane. 
 
The permeability studies of optimized (O1) formulation 
were carried out across rat and cadaver skin and nylon 66 
model membranes. Comparative studies showed slower drug 
permeation in human cadaver skin as compared to rat skin. 
Human skin is a multilayered organ which causes an efficient 
permeation obstacle for exogenous molecules53.  The rank 
order of drug permeation from optimized (O1) patch was 
found to be Nylon membrane> rat skin >cadaver skin (Figure 
5). Cumulative percent drug permeation order of three 
different model membranes was found to be 92.3 %> 86.28 
% > 63.42 % and flux value was to be 6.073>5.442> 
2.219µg/h/cm2 respectively. 
Skin irritation study 
Skin irritation studies of optimized KTF transdermal patch 
average skin irritation score was about (erythema) 0.66 ± 
0.0173 and standard irritant formalin score (erythema) 2.50 
± 0.0473. According to Draize test27, compounds producing 
scores of 2 or less are considered as safe for use on skin (no 
skin irritation). Thus we may infer that none of the 
components of the patch will result in skin irritation and 
consequent discomfort. 
Pharmacodynamic studies (Carrageenan induced hind 
paw edema model) 
Development of paw edema in rats induced by carrageenan 
is commonly correlated with the early exudative stage of 
inflammation, one of the important processes of 
inflammatory pathology54.  Carrageenan is a sulphated 
polysaccharide obtained from a sea weed (Rhodophyceae)55. 
In this test the efficacy of the optimized KTF transdermal 
patch was compared with orally administered KTF. The 
Rao et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(2):197-205 
ISSN: 2250-1177                                                                                  [204]                                                                                 CODEN (USA): JDDTAO 
percent paw swelling for each group is given in comparative 
plot of percent paw swelling (Figure 6). The average percent 
paw swelling reduction values of all groups were compared 
statistically using one-way ANOVA. The percent paw 
swelling for standard and test group was significantly less 
than the control group (p<0.01). However, there wasn't any 
significant difference in the efficacy of the oral KTF and 
transdermal patches (p>0.05). The average percent paw 
swelling of KTF patch and KTF oral suspension was found to 
be 58.60 ±6.34 and 64.39 ±3.86 respectively. Hence, it can be 
concluded that the KTF transdermal patches are as effective 
as the orally administered drug. However chronic oral 
administration of KTF or other NSAIDS for symptomatic 
treatment of arthritis results in severe gastric irritation and 
ulceration which is absent in transdermal delivery. Thus we 
may conclude that a transdermal NSAID patch is more 
effective without the concomitant gastric damage. 
 
Figure 6: Comparative plot of percent paw swelling. 
( ) control (  ) oral suspension                                  
(  ) KTF transdermal patch 
Stability studies 
In order to determine the change in physicochemical 
parameter on storage, stability studies were carried out. The 
physicochemical parameter of the optimized O1 formulation 
did not significantly change on storage. The thickness, 
percent dug content, flatness and folding endurance of the 
optimized patch was found to be 0.25±0.20mm, 
97.32±0.14%, 98.87±0.19% and 429±0.43 respectively. The 
patch retained its original properties even after exposure to 
accelerated conditions of temperature and humidity. 
CONCLUSION 
In the present study transdermal patches of KTF were 
developed using a hydrophilic and hydrophobic polymeric 
matrix of HPMC E5 and EGT S100. Formulation containing 
higher concentration polymer HPMC E5 and plasticizer PG 
showed maximum values of flux, tensile strength, 
bioadhesion and physicochemical parameters because 
polymer and plasticizer having its hydrophilic nature. Ex vivo 
permeation studies concluded that permeation of drug from 
patch in different skin membrane up to 8h. It also concluded 
that the KTF transdermal patches are as effective as the 
orally administered drug. However chronic oral 
administration of KTF or other NSAIDS for symptomatic 
treatment of arthritis results in severe gastric irritation and 
ulceration which is absent in transdermal delivery. Thus we 
may conclude that a transdermal NSAID patch is more 
effective without the concomitant gastric damage. Stability 
studies concluded that the patch retained its original 
properties even after exposure to accelerated conditions of 
temperature and humidity. 
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